77 research outputs found
SP397FETUIN-A ATTENUATES MINERAL NANOPARTICLE ACTIVATION OF THE NLRP3 INFLAMMASOME IN THE HUMAN MACROPHAGE
SaO024CALCIPROTEIN PARTICLE RIPENING INDUCES RUNX2-INDEPENDENT MINERALISATION OF HUMAN AORTIC VASCULAR SMOOTH MUSCLE CELLS
Relaxin-1–deficient mice develop an age-related progression of renal fibrosis
Relaxin-1–deficient mice develop an age-related progression of renal fibrosis.BackgroundRelaxin (RLX) is a peptide hormone that stimulates the breakdown of collagen in preparation for parturition and when administered to various models of induced fibrosis. However, its significance in the aging kidney is yet to be established. In this study, we compared structural and functional changes in the kidney of aging relaxin-1 (RLX-/-) deficient mice and normal (RLX+/+) mice.MethodsThe kidney cortex and medulla of male and female RLX+/+ and RLX-/- mice at various ages were analyzed for collagen content, concentration, and types. Histologic analysis, reverse transcription-polymerase chain reaction (RT-PCR) of relaxin and relaxin receptor mRNA expression, receptor autoradiography, glomerular isolation/analysis, and serum/urine analysis were also employed. Relaxin treatment of RLX-/- mice was used to confirm the antifibrotic effects of the peptide.ResultsWe demonstrate an age-related progression of renal fibrosis in male, but not female, RLX-/- mice with significantly (P < 0.05) increased tissue dry weight, collagen (type I) content and concentration. The increased collagen expression in the kidney was associated with increased glomerular matrix and to a lesser extent, interstitial fibrosis in RLX-/- mice, which also had significantly increased serum creatinine (P < 0.05) and urinary protein (P < 0.05). Treatment of RLX-/- mice with relaxin in established stages of renal fibrosis resulted in the reversal of collagen deposition.ConclusionThis study supports the concept that relaxin may provide a means to regulate excessive collagen deposition during kidney development and in diseased states characterized by renal fibrosis
Explanting Is an Ex Vivo Model of Renal Epithelial-Mesenchymal Transition
Recognised by their
de novo expression of alpha-smooth muscle actin
(SMA), recruitment of myofibroblasts is key to
the pathogenesis of fibrosis in chronic kidney
disease. Increasingly, we realise that
epithelial-mesenchymal transition (EMT) may be an
important source of these cells. In this study
we describe a novel model of renal EMT. Rat
kidney explants were finely diced on
gelatin-coated Petri dishes and cultured in
serum-supplemented media. Morphology and
immunocytochemistry were used to identify
mesenchymal (vimentin+, α-smooth muscle
actin (SMA)+, desmin+), epithelial
(cytokeratin+), and endothelial (RECA+) cells at
various time points. Cell outgrowths were all
epithelial in origin (cytokeratin+) at day 3. By
day 10, 50 ± 12%
(mean ± SE) of cytokeratin+
cells double-labelled for SMA, indicating EMT.
Lectin staining established a proximal tubule
origin. By day 17, cultures consisted only of
myofibroblasts (SMA+/cytokeratin−). Explanting
is a reproducible ex vivo model
of EMT. The ability to modify this change in
phenotype provides a useful tool to study the
regulation and mechanisms of renal
tubulointerstitial fibrosis
Fibrosis in the kidney: is a problem shared a problem halved?
Fibrotic disorders are commonplace, take many forms and can be life-threatening. No better example of this exists than the progressive fibrosis that accompanies all chronic renal disease. Renal fibrosis is a direct consequence of the kidney's limited capacity to regenerate after injury. Renal scarring results in a progressive loss of renal function, ultimately leading to end-stage renal failure and a requirement for dialysis or kidney transplantation
1115 A HEAD-TO-HEAD COMPARISON OF THE ANTI-FIBROTIC EFFICACY OF RELAXIN TO A CLINICALLY USED ACE INHIBITOR (ENALAPRIL)
- …
